NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings (NASDAQ:MEDP) issued its quarterly earnings data on Monday, February, 26th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.38 by $0.01. The business had revenue of $99.45 million for the quarter, compared to the consensus estimate of $97.25 million. Medpace had a return on equity of 10.55% and a net margin of 8.97%. The business's revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.35 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Medpace.

Medpace issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share guidance of $1.82 to $1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.80. The company issued revenue guidance of $412 million to $428 million, compared to the consensus revenue estimate of $423.58 million.

8 analysts have issued 12-month price targets for Medpace's stock. Their forecasts range from $35.00 to $42.00. On average, they expect Medpace's stock price to reach $37.40 in the next year. View Analyst Ratings for Medpace.

Medpace saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 426,813 shares, a decline of 31.6% from the February 28th total of 624,254 shares. Based on an average trading volume of 257,372 shares, the short-interest ratio is presently 1.7 days. Currently, 5.0% of the shares of the stock are short sold.

Some companies that are related to Medpace include Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and Cleveland BioLabs (CBLI).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Media headlines about MEDP stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of 0.16 on Accern's scale. They also gave media coverage about the company an impact score of 47.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $36.64.

Medpace has a market capitalization of $1.34 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]